



450 international health innovation finance players will gather in Paris on June 24th and 25th 2019 for the HealthTech Investor Days (HTID®)

The first edition of HTID® draws attention from international investors, pharmaceutical companies and the European health innovation ecosystem

HTID® positions itself as a "growth accelerator" for future European HealthTech unicorns

Future medicine and financing challenges will be addressed through 10 thematic conferences

Paris (France), May 24th, 2019 – The first edition of [HealthTech Investor Days \(HTID®\)](#), under the high patronage of the President of the French Republic, **Mr. Emmanuel MACRON**, will gather the most promising European HealthTech companies (Biotech, Medtech, Digital Health and Artificial Intelligence), major pharmas and international investment funds on **June 24-25th, 2019** in Paris (France).

"HTID® is a unique European platform for discussions between innovative HealthTech companies, international financial organizations and major healthcare companies. Its objective is to foster synergy and promote collaborations between all these players, and to accelerate the marketing of new medicines and therapeutic solutions," explains **Maryvonne Hiance, Chairman of France Biotech**, which is a French nonprofit organization and the event's creator

HTID®'s goal is to highlight Europe's most mature health innovation companies looking to finance their final development stages. *"Europe has a multitude of innovative healthcare companies and technologies. HTID®, organized by France Biotech, will be an opportunity for us to gather international investors, pharmaceutical and industrial partners as well as the entire health tech ecosystem in the same place,"* says **Jean-Manuel Fontaine, VP External and Scientific Affairs at Mithra Pharmaceuticals**.

For two days, HTID® will combine one-on-one meetings and plenary sessions about health innovation, and its key trends and drivers. Almost 450 international experts will attend these meetings:

- **Top management from approximately 90 HealthTech companies**, selected for their maturity (advanced clinical trials or successful first rounds of funding).
Although registration is still open, nine countries are already represented including Belgium (Mithra Pharmaceuticals, Celyad and Sequana Medical), France (Genfit, Nanobiotix and Pixium Vision), Germany (Curevac, Heidelberg Pharma and Hepa Wash GmbH), Sweden (Isofol Medical) and the UK (Stilla Technologies).

- **Top management of some 15 major healthcare companies** including Amgen (USA), Boehringer Ingelheim (Germany), Guerbet (France), Ipsen (France), Mediolanum (Italy), Menarini (Italy), Medtronic (USA), Pfizer (USA), Sanofi (France), Servier (France), Takeda (Japan) and Thea Pharma (France).
- **About 50 international investors already enrolled in the HTID®.**
This first round of participants is highly diversified (international banks, insurance companies, investment banks, fund managers, private equity firms, etc.) and covers many countries (China, Dubai, Spain, USA, etc.).
- **Around 50 international experts and speakers at the ten HTID® conferences.**
Among them, French and European ecosystem key players in health innovation (EuropaBio, EITHEALTH, LEEM, EIB, etc.), academic researchers (University of Chicago, Harvard Medical School, Paris Descartes University, etc.) and managers of major financial and stock exchange institutions (Société Générale, BNP Paribas, Euronext, Nasdaq, etc.).

International Access: A live broadcast and a direct live stream will be available during the event for companies from the Peninsula Hotel Business Center (Paris, France) to Business France (New-York, USA). A direct live stream from Shanghai (China) will also be available for investors.

Find the plenary conferences program on HTID® website: www.htid-paris.com

France Biotech's members who won't be able to attend the HTID® can follow broadcast of plenary conferences directly on France Biotech's Intranet.

The conferences will be open to the media.
Accreditation requests must be sent via email to francebiotech@alizerp.com.

About France Biotech

Created in 1997, France Biotech is a French nonprofit organization that brings together the country's leading innovative health companies and their expert partners (investors, lawyers, research institutes, clusters, etc.). Its core mission is to promote health innovation in France and help the sector's start-up companies and SMEs to become successful organizations, capable of rapidly developing new therapeutic solutions. France Biotech is chaired by Maryvonne Hiance and has two hundred members. www.france-biotech.fr

Press contacts

ALIZE RP - Europe

Caroline Carmagnol / Tatiana Vieira
francebiotech@alizerp.com
+336 64 18 99 59 / +336 47 38 90 04 / +336 31 13 76 20

France Biotech

Maryvonne Hiance
Chairman
mhiance@france-biotech.org

RooneyPartners LLC – North America

Marion Janic / Kate Barrette
mjanic@rooneyco.com / kbarrette@rooneyco.com
+1.212.223.4017 / +1.212.223.0561

For more information on HTID®, contact Sophie Villedieu (sophie.villedieu@france-biotech.org) and Nathalie Donne (nathalie.donne@shapenlink.com)

Our partners:

Super Gold:



Silver:



Bronze:



Our organizational supporters:



Our supporters:

